Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6189797 | 0.87 | NR1H2 (0.63) | NR1H2ESR2HRH3MAPTF10 | |
| SCHEMBL1266229 | 0.87 | NR1H2 (0.63) | NR1H2ESR2HRH3MAPTF10 | |
| SCHEMBL22755613 | 0.87 | NR1H2 (0.63) | NR1H2ESR2HRH3MAPTF10 | |
| SCHEMBL18209393 | 0.87 | NR1H2 (0.63) | NR1H2ESR2HRH3MAPTF10 | |
| SCHEMBL21659498 | 0.86 | NR1H2 (0.62) | NR1H2ESR2HRH3MAPTF10 | |
| SCHEMBL31013888 | 0.85 | NR1H2 (0.61) | NR1H2ESR2HRH3F10ABHD6 | |
| SCHEMBL30390692 | 0.85 | NR1H2 (0.70) | NR1H2ESR2MAPTABHD6MAPK1 | |
| SCHEMBL6438594 | 0.85 | NR1H2 (0.70) | NR1H2ESR2MAPTABHD6MAPK1 | |
| SCHEMBL29097838 | 0.85 | ESR2 (0.58) | NR1H2ESR2HRH3MAPTGPR119 | |
| SCHEMBL30199070 | 0.85 | ESR2 (0.58) | NR1H2ESR2HRH3MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| EP-1070714-B1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | NR1H2 507/4885ESR2 3064/4885HRH3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.